
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
A 62-Year-Old Male With Stage III Non-Small Cell Lung Cancer
Case: A 62-Year-Old Male With Stage III NSCLC
Initial presentation
Clinical workup
Treatment


